VALNEVA : Résultat de la réunion CDC-ACIP

M9321184

17 avr. 2025 •15:29

CDC ACIP Meeting Examines Next Steps for Meningococcal, RSV, and Chikungunya Vaccination
April 16, 2025
....
Vote 3: ACIP recommends the live attenuated chikungunya vaccine for individuals aged 18 years and younger who are traveling to a country or territory experiencing a chikungunya outbreak, with the same considerations as Vote 1.

Meeting discussion highlights:

The ACIP based its review of Valneva’s Virus-like Particle Chikungunya vaccine for use in adolescent and adult travelers, laboratory personnel, and pregnant or breastfeeding individuals. Surveillance data for the live attenuated chikungunya vaccine, particularly for travelers, were discussed. A safety review of Valneva’s vaccine (CHIK-LA) identified six serious adverse events, including five hospitalizations and one outpatient visit. At least one CISA expert found a plausible link between the adverse events and the vaccine. Experts noted challenges in distinguishing vaccine-related adverse events from common reactogenicity, especially in older adults with comorbidities.